Zinger Key Points
- Biodexa announces positive findings from the Phase 2 clinical trial of eRapa.
- The findings will be presented at the 2024 Digestive Disease Week annual meeting.
- Discover Fast-Growing Stocks Every Month
Biodexa Pharmaceuticals BDRX stock is trading higher. The company on Tuesday announced progress towards the treatment of Familial Adenomatous Polyposis.
What Happened: Biodexa, a clinical-stage biopharmaceutical company dedicated to acquiring and developing innovative solutions for diseases with unmet medical needs, has announced positive statistically significant findings from the Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis.
During the trial, patients were divided into three groups of 10, receiving different doses of the treatment over 12 months. Endoscopic exams were conducted at the start and after six months to evaluate safety, tolerability and changes in polyp size.
The results of the experiment showed eRapa, an oral tablet formulation of rapamycin, appeared safe and well-tolerated with a significant 24% reduction in the total polyp burden at six months compared with baseline, as well as an overall 83% non-progression rate.
The results of the Phase 2 trial based on six month data are scheduled for presentation at the 2024 Digestive Disease Week annual meeting in Washington D.C.
Related Link: Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
How To Buy BDRX Stock
By now you're likely curious about how to participate in the market for Biodexa Pharmaceuticals – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share. In the case of Biodexa Pharmaceuticals, which is trading at $2.28 as of publishing time, $100 would buy you 43.86 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
BDRX Price Action: At the time of writing, Biodexa Pharmaceuticals shares were up 78.4% at $2.20, according to Benzinga Pro.
Image: 911619 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.